These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 31210948)

  • 1. Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
    Preda CM; Baicus C; Sandra I; Oproiu A; Manuc T; Constantinescu I; Gavrila D; Diculescu M; Dumitru R; Vasilescu C; Tieranu C; Istratescu D; Voiosu T; Manuc M
    United European Gastroenterol J; 2019 Jun; 7(5):699-708. PubMed ID: 31210948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
    Krastev Z; Jelev D; Antonov K; Petkova T; Atanasova E; Zheleva N; Tomov B; Boyanova Y; Mateva L
    World J Gastroenterol; 2016 Feb; 22(8):2630-5. PubMed ID: 26937151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
    Klibanov OM; Gale SE; Santevecchi B
    Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
    Flisiak R; Janczewska E; Łucejko M; Karpińska E; Zarębska-Michaluk D; Nazzal K; Bolewska B; Białkowska J; Berak H; Fleischer-Stępniewska K; Tomasiewicz K; Karwowska K; Simon K; Piekarska A; Tronina O; Tuchendler E; Garlicki A
    J Viral Hepat; 2018 Nov; 25(11):1298-1305. PubMed ID: 29888828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
    Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
    Cheng EY; Saab S; Holt CD; Busuttil RW
    Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
    Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
    Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
    Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
    Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
    Forns X; Poordad F; Pedrosa M; Berenguer M; Wedemeyer H; Ferenci P; Shiffman ML; Fried MW; Lovell S; Trinh R; Lopez-Talavera JC; Everson G
    Liver Int; 2015 Nov; 35(11):2358-62. PubMed ID: 26248955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin.
    Manea ED; Stefan I; Olariu C; Calina OC; Jipa RE; Hristea A
    Acta Gastroenterol Belg; 2018; 81(1):9-13. PubMed ID: 29562372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
    Trifan A; Stanciu C; Gheorghe L; Iacob S; Curescu M; Cijevschi Prelipcean C; Stefanescu G; Girleanu I; Chiriac S; Mihai C; Brisc C; Goldis A; Sporea I; Miftode E; Bataga S; Rogoveanu I; Preda C; Caruntu FA; Singeap AM
    Medicine (Baltimore); 2017 Dec; 96(50):e9271. PubMed ID: 29390377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
    Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ;
    Int J Drug Policy; 2018 Dec; 62():94-103. PubMed ID: 30384028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
    J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
    Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
    Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?
    Asselah T; Bruno S; Craxi A
    J Hepatol; 2014 Dec; 61(6):1430-3. PubMed ID: 25149112
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
    Preda CM; Popescu CP; Baicus C; Voiosu TA; Manuc M; Pop CS; Gheorghe L; Sporea I; Trifan A; Tantau M; Tantau A; Ceausu E; Proca D; Constantinescu I; Ruta SM; Diculescu MM; Oproiu A
    Liver Int; 2018 Apr; 38(4):602-610. PubMed ID: 28816020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
    Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
    Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
    Feld JJ; Kowdley KV; Coakley E; Sigal S; Nelson DR; Crawford D; Weiland O; Aguilar H; Xiong J; Pilot-Matias T; DaSilva-Tillmann B; Larsen L; Podsadecki T; Bernstein B
    N Engl J Med; 2014 Apr; 370(17):1594-603. PubMed ID: 24720703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
    Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
    Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.